- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Health
IO Biotech floats in $100m IPO
The Lundbeck and Novo-backed cancer therapy developer priced its shares at the bottom of their range in an upsized offering.
Nov 8, 2021Analysis: ABL raises $370m in series B
Satellite launch vehicle developer ABL Space Systems raised a multimillion dollar series B round, which took its total funding to $420m with a $200m extension to its latest round.
Nov 8, 2021SoftBank accompanies Papa to $150m series D
SoftBank led the companionship service provider's latest round, pushing its total funding to $240m.
Nov 5, 2021Bit.bio bids hello to $103m
Tencent, Charles River Laboratories and National Resilience all backed the stem cell technology developer’s series B round.
Nov 5, 2021Fuelling energy technologies that can save the planet
While COP26 is about to start and the representatives of almost 200 countries prepare to gather in Glasgow for what has been described as “the world’s best last chance to get runaway climate change under control”, the energy industry is in the middle of a profound metamorphosis that could radically reshape global power production and transform our relationship with the planet’s natural resources.
Nov 5, 2021Solid returns are key to realising zero emissions goal
Global Energy Council Q4 2021 editorial by James Mawson, editor in chief, Global Corporate Venturing
Nov 5, 2021Daily Deal Round Up: November 4, 2021
Ubicom Holdings Japan helped gynaecological imaging software developer Illumigyn take its total funding to $33m while Optum took part in a $30m round for health payment technology provider Medallion.
Nov 4, 2021Biolinq patches in corporates to raise $100m
The wearable glucose monitor developer’s nine-figure series B round included M Ventures, Hikma Ventures, Axa Investment Management, Ascencia, Hikm Taisho, Cirrus Logic and EOFlow.
Nov 4, 2021Cambridge Epigenetix sequences $88m in funding
Alphabet returned to reinvest in the epigenetics diagnostics technology developer through a series D round that took its total funding to about $145m.
Nov 4, 2021Clade Therapeutics clasps $87m
Bristol Myers Squibb was among the participants in cellular therapy developer Clade Therapeutics' series A round, with the proceeds to go to platform development.
Nov 4, 2021Corporates enter Parthenon in $65m series A
Cancer drug developer Parthenon Therapeutics secured the funding in a series A round co-led by Pfizer Ventures and Taiho Ventures.
Nov 4, 2021Featured Content
GCVI Summit 2026 RewindRewatch the sessions, recap the learningsGCVI Summit 2026 Rewind
Rewatch the sessions, recap the learnings
The World of Corporate VenturingGCV's annual report on the state of the corporate investment sectorThe World of Corporate Venturing
GCV's annual report on the state of the corporate investment sector
GCV’s Rising Stars and Emerging Leaders 2026The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.GCV’s Rising Stars and Emerging Leaders 2026
The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
